Actinium Pharmaceuticals Inc (ATNM)
$1.78
+0.06
(+3.49%)▲
Performance
- $1.68$1.79$1.78
5.62%
Downside
Day's Volatility :6.15%
Upside
0.56%
- $1.33$10.24$1.78
25.28%
Downside
52 Weeks Volatility :87.01%
Upside
82.62%
Returns
| Period | Actinium Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -77.64% | 0.0% |
6 Months | -76.61% | 0.0% |
1 Year | -72.36% | 0.0% |
3 Years | -70.96% | -22.3% |
Highlights
Market Capitalization | 55.5M |
Book Value | $1.44 |
Earnings Per Share (EPS) | -1.56 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.8 |
Profit Margin | 0.0% |
Operating Margin TTM | -57665.44% |
Return On Assets TTM | -30.91% |
Return On Equity TTM | -87.96% |
Revenue TTM | 81.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.0M |
EBITDA | -46.5M |
Diluted Eps TTM | -1.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.37 |
EPS Estimate Next Year | -0.72 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.43 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 225.84%
Technicals Summary
Sell
Neutral
Buy
Actinium Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Actinium Pharmaceuticals Inc | -15.24% | -76.61% | -72.36% | -70.96% | -72.82% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Actinium Pharmaceuticals Inc | NA | NA | 0.0 | -1.37 | -0.88 | -0.31 | NA | 1.44 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Actinium Pharmaceuticals Inc | Buy | $55.5M | -72.82% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Actinium Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 114.0K → 81.0K (in $), with an average decrease of 29.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -8.67M → -11.35M (in $), with an average decrease of 31.0% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 109.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 140.2%
Company Information
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
Organization | Actinium Pharmaceuticals Inc |
Employees | 49 |
CEO | Mr. Sandesh C. Seth M.B.A., M.S. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.78
+3.49%
Keyarch Acquisition Corp
$1.78
+3.49%
Connexa Sports Technologies Inc
$1.78
+3.49%
Us Value Etf
$1.78
+3.49%
First Wave Biopharma Inc
$1.78
+3.49%
Global X Msci Next Emerging
$1.78
+3.49%
Fat Projects Acquisition Corp
$1.78
+3.49%
Capital Link Global Fintech
$1.78
+3.49%
Applied Uv Inc
$1.78
+3.49%